Literature DB >> 26116531

Niclosamide, an anti-helminthic molecule, downregulates the retroviral oncoprotein Tax and pro-survival Bcl-2 proteins in HTLV-1-transformed T lymphocytes.

Di Xiang1, Yunsheng Yuan1,2, Li Chen3,4, Xin Liu1, Chandra Belani1, Hua Cheng4,5,6,7.   

Abstract

Adult T cell leukemia and lymphoma (ATL) is a highly aggressive form of hematological malignancy and is caused by chronic infection of human T cell leukemia virus type 1 (HTLV-1). The viral genome encodes an oncogenic protein, Tax, which plays a key role in transactivating viral gene transcription and in deregulating cellular oncogenic signaling to promote survival, proliferation and transformation of virally infected T cells. Hence, Tax is a desirable therapeutic target, particularly at early stage of HTLV-1-mediated oncogenesis. We here show that niclosamide, an anti-helminthic molecule, induced apoptosis of HTLV-1-transformed T cells. Niclosamide facilitated degradation of the Tax protein in proteasome. Consistent with niclosamide-mediated Tax degradation, this compound inhibited activities of MAPK/ERK1/2 and IκB kinases. In addition, niclosamide downregulated Stat3 and pro-survival Bcl-2 family members such as Mcl-1 and repressed the viral gene transcription of HTLV-1 through induction of Tax degradation. Since Tax, Stat3 and Mcl-1 are crucial molecules for promoting survival and growth of HTLV-1-transformed T cells, our findings demonstrate a novel mechanism of niclosamide in inducing Tax degradation and downregulating various cellular pro-survival molecules, thereby promoting apoptosis of HTLV-1-associated leukemia cells.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Down-regulation; HTLV-1; Niclosamide; Tax

Mesh:

Substances:

Year:  2015        PMID: 26116531      PMCID: PMC4580622          DOI: 10.1016/j.bbrc.2015.06.120

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

Review 1.  Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: hijacking cellular IkappaB kinases.

Authors:  S C Sun; D W Ballard
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

2.  HTLV: the virus of adult T-cell leukaemia in Japan and elsewhere.

Authors:  R C Gallo; W A Blattner; M S Reitz; Y Ito
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

3.  Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.

Authors:  Ulrike Sack; Wolfgang Walther; Dominic Scudiero; Mike Selby; Dennis Kobelt; Margit Lemm; Iduna Fichtner; Peter M Schlag; Robert H Shoemaker; Ulrike Stein
Journal:  J Natl Cancer Inst       Date:  2011-06-17       Impact factor: 13.506

Review 4.  Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy.

Authors:  M Matsuoka; K-T Jeang
Journal:  Oncogene       Date:  2010-11-29       Impact factor: 9.867

5.  Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1.

Authors:  Levi J Beverly; William W Lockwood; Parag P Shah; Hediye Erdjument-Bromage; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-10       Impact factor: 11.205

6.  IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain.

Authors:  H Sakurai; H Chiba; H Miyoshi; T Sugita; W Toriumi
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

7.  STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling.

Authors:  Christina M Ulane; Jason J Rodriguez; Jean-Patrick Parisien; Curt M Horvath
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 8.  The role of ubiquitin in NF-kappaB regulatory pathways.

Authors:  Brian Skaug; Xiaomo Jiang; Zhijian J Chen
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

9.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

10.  HTLV-1 Tax deregulates autophagy by recruiting autophagic molecules into lipid raft microdomains.

Authors:  T Ren; Y Takahashi; X Liu; T P Loughran; S-C Sun; H-G Wang; H Cheng
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

View more
  5 in total

1.  JAK2/STAT3 pathway as a therapeutic target in ovarian cancers.

Authors:  Tomoyuki Yoshikawa; Morikazu Miyamoto; Tadashi Aoyama; Hiroaki Soyama; Tomoko Goto; Junko Hirata; Ayako Suzuki; Isao Nagaoka; Hitoshi Tsuda; Kenichi Furuya; Masashi Takano
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

2.  Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells.

Authors:  Shunyan Weng; Liang Zhou; Qing Deng; Jiaxian Wang; Yan Yu; Jianwei Zhu; Yunsheng Yuan
Journal:  BMC Gastroenterol       Date:  2016-02-25       Impact factor: 3.067

Review 3.  The role of IL-10 in Mycobacterium avium subsp. paratuberculosis infection.

Authors:  Tariq Hussain; Syed Zahid Ali Shah; Deming Zhao; Srinand Sreevatsan; Xiangmei Zhou
Journal:  Cell Commun Signal       Date:  2016-12-01       Impact factor: 5.712

4.  Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line.

Authors:  Benxu Cheng; Liza Doreen Morales; Yonghong Zhang; Shizue Mito; Andrew Tsin
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

5.  Niclosamide sensitizes nasopharyngeal carcinoma to radiation by downregulating Ku70/80 expression.

Authors:  Jingjing Li; Haiwen Li; Dechao Zhan; Mei Xiang; Jun Yang; Yufang Zuo; Yin Yu; Hechao Zhou; Danxian Jiang; Haiqing Luo; Zihong Chen; Zhonghua Yu; Zumin Xu
Journal:  J Cancer       Date:  2018-02-06       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.